A weight loss drug group scored younger on body age tests in a trial

A trial designed to study body fat has produced a finding about aging. After the trial closed, investigators returned to blood that had been frozen along the way and ran it through tools that estimate how old a body looks, rather than how many years it has lived. The results were published in Nature Communications in May 2026 [1].

The trial the samples came from

The original study was a randomised controlled trial: participants were assigned by chance to receive either semaglutide or a placebo, an inactive substitute given so that investigators can separate what the drug did from what would have happened anyway. Eighty four adults living with HIV took part, all of them with lipohypertrophy, a build up of fat in places on the body where it does not normally gather. Forty five were assigned to semaglutide and thirty nine to placebo, and the study ran for 32 weeks with neither side knowing who had received which until it was over [1].

Its stated question was about fat. Aging entered later, when the team went back to stored samples and measured something the trial had never been built to answer. That distinction runs through everything below [1][2].

What the tools measure

The tools are called epigenetic clocks. Cells carry small chemical marks on their DNA that help decide which genes are switched on, and the pattern of those marks shifts with age in ways a statistical model can be trained to read. Fed a blood sample, such a model returns a number: an estimate of biological age, which can sit above or below the age on a person's birth certificate [1].

The analysis used several of these models rather than one, because they are not interchangeable. Each was trained on a different target, so each is really a separate estimate of the same loose idea. One of the three, DunedinPACE, reports a rate rather than a total: not how old the body looks, but how quickly the marks are piling up during the period being measured [1].

What the re-analysis reported

On PhenoAge, the semaglutide group came out about 4.9 years younger than the placebo group, with a P value of 0.004. On PCGrimAge the gap was about 3.1 years, at P equals 0.007. DunedinPACE, the rate measure, ran about 9 percent slower in the semaglutide group, at P equals 0.01. A P value of 0.004 means that a difference this large would be expected to appear by chance about four times in a thousand if the drug had done nothing at all [1].

The differences persisted after the investigators accounted for sex, body weight and inflammation, so weight reduction alone does not obviously explain them. What carries more weight than any single figure is the direction: every clock the team applied pointed the same way. The authors present the result as the first evidence from a randomised trial that a medicine of this kind can move these measures, in the population they studied [1][2].

Why the design caps what can be claimed

This was a post hoc analysis, meaning a question asked of the data after the fact rather than one the study was set up to answer. Nothing about that makes a result wrong. It does change how much it can carry: the size of the study was chosen for the fat measurements, no aging outcome was named in advance, and analyses of stored samples are where new hypotheses are generated rather than confirmed [1].

The population is narrow as well. These were adults living with HIV and a specific pattern of fat build up, which is not the general population, and 32 weeks is a short window in which to observe anything described as aging. Whether the same shift appears in other groups, or holds over years rather than months, is untested [1].

There is also the gap between a marker and an outcome. A clock reading is a laboratory measurement, not a record of health or of years lived. How tightly movement in these measures tracks anything a person would notice remains an open research question, and a trial that moved a clock is not the same as a trial that changed a life [1][2].

A separate question about the same family of medicines

Elsewhere, laboratory groups have turned to a separate question about the same class of medicine. At the University of Colorado Anschutz Cancer Center, researchers are testing whether these medicines act on immune cells directly, rather than only through appetite and blood sugar. The reasoning begins with a pattern visible across large populations, in which obesity travels with raised rates of several cancers, and works downwards to individual cells [3].

That work is at an early stage: experiments in cells, no published clinical trial, no figures worth quoting yet, and an application for federal funding to continue. It sits in this briefing for a single reason: the receptor these medicines act on appears on a wider range of cell types than the weight loss account ever needed, and that is the sort of observation that makes an aging result worth testing properly [3].

What would settle it

A trial that names biological age as its main measurement before it begins, in a broader group of participants, running long enough for the estimate to mean something. Until then the honest description of this result is a strong signal from a small trial, found by looking again at samples that had already been collected, in patients whose situation was unusual. Coverage that has reduced it to a claim that a weight loss medicine slows aging is reporting something the study did not test [1][4].